
LINK . SPRINGER . COM {
}
Title:
Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial | Journal of Cancer Research and Clinical Oncology
Description:
Introduction While some clinical studies have shown that PD-1 and PD-L1 can also be an effective neoadjuvant treatment for early-stage non-small cell lung cancer (NSCLC), no evidence has been available for the use of the PD-1 inhibitor sintilimab combined with chemotherapy as a neoadjuvant treatment for potentially resectable NSCLC in the Chinese population. Methods This prospective, single-center, single-arm, phase 2 clinical trial (registration number: NCT04326153) included treatment-naive patients with potentially resectable NSCLC (stage IIIA/IIIB) who received sintilimab plus nab-paclitaxel and carboplatin for two to three cycles before systematic nodal dissection 30 to 45 days after neoadjuvant treatment. After surgery, patients needed to complete two cycles of adjuvant chemoimmunotherapy (sintilimab + nab-paclitaxel + carboplatin). The primary endpoint was disease-free survival rate at 24 months, whereas secondary endpoints included major pathological response (MPR) and pathologic complete response (pCR) rates, the proportion of patients who achieved tumor downstaging, overall survival, objective response rate (ORR), and adverse effects. PD-L1 status before and after treatment was also determined. Results Among the 20 patients who received neoadjuvant chemoimmunotherapy, 16 underwent radical resection. The disease control rate and ORR were 90% and 70%, respectively. Among the 16 patients who underwent surgery, 10 (62.5%) and 5 (31.25%) achieved MPR and pCR, respectively. Squamous cell NSCLC exhibited superior response rates compared to adenocarcinoma (pCR 35.7% vs. 0%). Moreover, 14 patients (70%) experienced grade 1 or 2 neoadjuvant treatment-related adverse events (TRAEs), whereas 6 (30%) experienced grade 3 TRAEs. Bronchopleural fistula (BPF) was found in the current study as an adverse reaction of concern. The rate of BPF was 20% (4/20), of which three patients were in grade 1–2, and one patient died. The occurrence of BPF had no significant correlation with basic disease history, nutritional status, anemia, hypoalbuminemia, surgical procedure, pathological remission, and PD-L1 expression. However, during neoadjuvant treatment, no adverse events prompted dose reduction, treatment discontinuation, surgery delay, or death. Although PD-L1 expression may change after chemoimmunotherapy, no regular pattern was noted. PD-L1 expression, neither at baseline nor after neoadjuvant chemoimmunotherapy, was associated with pathological remission. Conclusions The current study found similar ORR, slightly lower MPR and pCR rates, and lower grade 3 TRAEs among patients with potentially resectable stage IIIA/IIIB NSCLC compared to the NADIM trial, as well as a greater ORR, MPR rate, pCR rate, and grade 3 TRAEs compared to Gao’s study involving sintilimab for Chinese patients with resectable stage IA–IIIB NSCLC. Though neoadjuvant chemoimmunotherapy had been found to promote a high risk of BPF for patients with stage IIIA/IIIB disease, it offered greater potential for radical cure. Therefore, the current study suggests that neoadjuvant chemoimmunotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {📚}
- Education
- Health & Fitness
- Science
Content Management System {📝}
What CMS is link.springer.com built with?
Custom-built
No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of link.springer.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {💸}
The income method remains a mystery to us.
Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.
Keywords {🔍}
article, cancer, pubmed, google, scholar, lung, neoadjuvant, patients, cell, resectable, nonsmall, cas, chemotherapy, nsclc, response, oncol, data, treatment, phase, sintilimab, thorac, central, clinical, stage, trial, study, surgery, pathological, adverse, nonsmallcell, clin, management, singlearm, chemoimmunotherapy, rate, bronchopleural, fistula, ann, surg, jilin, potentially, liu, survival, pcr, events, advanced, access, privacy, cookies, content,
Topics {✒️}
stage iiia-n2 egfr-mutant month download article/chapter small-cell lung cancer stage iiia/iiib disease william wn jr small-cell lung cancers t-cell checkpoint inhibitors stage ii-iii stage iiia/iiib disease-free survival rate phase ii trial included treatment-naive patients advanced squamous nsclc lung cancer surgery major pathological response resectable lung cancer clinical oncology aims potentially resectable nsclc lung cancer resection resected lung cancer full article pdf privacy choices/manage cookies open window thoracostomy kewei ma systematic meta-analysis william wn zhiguang yang resectable locally advanced objective response rate pathologic complete response low-dose radiotherapy article sun stage iii sintilimab + nab-paclitaxel + carboplatin common terminology criteria response evaluation criteria neoadjuvant checkpoint blockade basic disease history advanced solid tumors disease control rate european economic area shi qiu code availability french database epithor erlotinib versus gemcitabine pathological effect interpretation clinical risk model neoadjuvant pd-1 inhibitor article journal xiaobo ma
Questions {❓}
- Chatwal MS, Tanvetyanon T (2018) Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?
Schema {🗺️}
WebPage:
mainEntity:
headline:Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
description:While some clinical studies have shown that PD-1 and PD-L1 can also be an effective neoadjuvant treatment for early-stage non-small cell lung cancer (NSCLC), no evidence has been available for the use of the PD-1 inhibitor sintilimab combined with chemotherapy as a neoadjuvant treatment for potentially resectable NSCLC in the Chinese population. This prospective, single-center, single-arm, phase 2 clinical trial (registration number: NCT04326153) included treatment-naive patients with potentially resectable NSCLC (stage IIIA/IIIB) who received sintilimab plus nab-paclitaxel and carboplatin for two to three cycles before systematic nodal dissection 30 to 45 days after neoadjuvant treatment. After surgery, patients needed to complete two cycles of adjuvant chemoimmunotherapy (sintilimab + nab-paclitaxel + carboplatin). The primary endpoint was disease-free survival rate at 24 months, whereas secondary endpoints included major pathological response (MPR) and pathologic complete response (pCR) rates, the proportion of patients who achieved tumor downstaging, overall survival, objective response rate (ORR), and adverse effects. PD-L1 status before and after treatment was also determined. Among the 20 patients who received neoadjuvant chemoimmunotherapy, 16 underwent radical resection. The disease control rate and ORR were 90% and 70%, respectively. Among the 16 patients who underwent surgery, 10 (62.5%) and 5 (31.25%) achieved MPR and pCR, respectively. Squamous cell NSCLC exhibited superior response rates compared to adenocarcinoma (pCR 35.7% vs. 0%). Moreover, 14 patients (70%) experienced grade 1 or 2 neoadjuvant treatment-related adverse events (TRAEs), whereas 6 (30%) experienced grade 3 TRAEs. Bronchopleural fistula (BPF) was found in the current study as an adverse reaction of concern. The rate of BPF was 20% (4/20), of which three patients were in grade 1–2, and one patient died. The occurrence of BPF had no significant correlation with basic disease history, nutritional status, anemia, hypoalbuminemia, surgical procedure, pathological remission, and PD-L1 expression. However, during neoadjuvant treatment, no adverse events prompted dose reduction, treatment discontinuation, surgery delay, or death. Although PD-L1 expression may change after chemoimmunotherapy, no regular pattern was noted. PD-L1 expression, neither at baseline nor after neoadjuvant chemoimmunotherapy, was associated with pathological remission. The current study found similar ORR, slightly lower MPR and pCR rates, and lower grade 3 TRAEs among patients with potentially resectable stage IIIA/IIIB NSCLC compared to the NADIM trial, as well as a greater ORR, MPR rate, pCR rate, and grade 3 TRAEs compared to Gao’s study involving sintilimab for Chinese patients with resectable stage IA–IIIB NSCLC. Though neoadjuvant chemoimmunotherapy had been found to promote a high risk of BPF for patients with stage IIIA/IIIB disease, it offered greater potential for radical cure. Therefore, the current study suggests that neoadjuvant chemoimmunotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.
datePublished:2022-02-22T00:00:00Z
dateModified:2022-02-22T00:00:00Z
pageStart:819
pageEnd:831
sameAs:https://doi.org/10.1007/s00432-021-03896-w
keywords:
Non-small cell lung cancer
Neoadjuvant
Chemoimmunotherapy
Sintilimab
Oncology
Cancer Research
Internal Medicine
Hematology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig2_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig3_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig4_HTML.png
isPartOf:
name:Journal of Cancer Research and Clinical Oncology
issn:
1432-1335
0171-5216
volumeNumber:149
type:
Periodical
PublicationVolume
publisher:
name:Springer Berlin Heidelberg
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Chao Sun
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Yunpeng Liu
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Peng Zhang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xu Wang
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Yinghui Xu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xingyu Lin
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xiaobo Ma
affiliation:
name:The First Hospital of Jilin University
address:
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Ye Guo
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Shi Qiu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Guoguang Shao
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Zhiguang Yang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Kewei Ma
url:http://orcid.org/0000-0003-2987-576X
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
description:While some clinical studies have shown that PD-1 and PD-L1 can also be an effective neoadjuvant treatment for early-stage non-small cell lung cancer (NSCLC), no evidence has been available for the use of the PD-1 inhibitor sintilimab combined with chemotherapy as a neoadjuvant treatment for potentially resectable NSCLC in the Chinese population. This prospective, single-center, single-arm, phase 2 clinical trial (registration number: NCT04326153) included treatment-naive patients with potentially resectable NSCLC (stage IIIA/IIIB) who received sintilimab plus nab-paclitaxel and carboplatin for two to three cycles before systematic nodal dissection 30 to 45 days after neoadjuvant treatment. After surgery, patients needed to complete two cycles of adjuvant chemoimmunotherapy (sintilimab + nab-paclitaxel + carboplatin). The primary endpoint was disease-free survival rate at 24 months, whereas secondary endpoints included major pathological response (MPR) and pathologic complete response (pCR) rates, the proportion of patients who achieved tumor downstaging, overall survival, objective response rate (ORR), and adverse effects. PD-L1 status before and after treatment was also determined. Among the 20 patients who received neoadjuvant chemoimmunotherapy, 16 underwent radical resection. The disease control rate and ORR were 90% and 70%, respectively. Among the 16 patients who underwent surgery, 10 (62.5%) and 5 (31.25%) achieved MPR and pCR, respectively. Squamous cell NSCLC exhibited superior response rates compared to adenocarcinoma (pCR 35.7% vs. 0%). Moreover, 14 patients (70%) experienced grade 1 or 2 neoadjuvant treatment-related adverse events (TRAEs), whereas 6 (30%) experienced grade 3 TRAEs. Bronchopleural fistula (BPF) was found in the current study as an adverse reaction of concern. The rate of BPF was 20% (4/20), of which three patients were in grade 1–2, and one patient died. The occurrence of BPF had no significant correlation with basic disease history, nutritional status, anemia, hypoalbuminemia, surgical procedure, pathological remission, and PD-L1 expression. However, during neoadjuvant treatment, no adverse events prompted dose reduction, treatment discontinuation, surgery delay, or death. Although PD-L1 expression may change after chemoimmunotherapy, no regular pattern was noted. PD-L1 expression, neither at baseline nor after neoadjuvant chemoimmunotherapy, was associated with pathological remission. The current study found similar ORR, slightly lower MPR and pCR rates, and lower grade 3 TRAEs among patients with potentially resectable stage IIIA/IIIB NSCLC compared to the NADIM trial, as well as a greater ORR, MPR rate, pCR rate, and grade 3 TRAEs compared to Gao’s study involving sintilimab for Chinese patients with resectable stage IA–IIIB NSCLC. Though neoadjuvant chemoimmunotherapy had been found to promote a high risk of BPF for patients with stage IIIA/IIIB disease, it offered greater potential for radical cure. Therefore, the current study suggests that neoadjuvant chemoimmunotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.
datePublished:2022-02-22T00:00:00Z
dateModified:2022-02-22T00:00:00Z
pageStart:819
pageEnd:831
sameAs:https://doi.org/10.1007/s00432-021-03896-w
keywords:
Non-small cell lung cancer
Neoadjuvant
Chemoimmunotherapy
Sintilimab
Oncology
Cancer Research
Internal Medicine
Hematology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig2_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig3_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_Fig4_HTML.png
isPartOf:
name:Journal of Cancer Research and Clinical Oncology
issn:
1432-1335
0171-5216
volumeNumber:149
type:
Periodical
PublicationVolume
publisher:
name:Springer Berlin Heidelberg
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Chao Sun
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Yunpeng Liu
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Peng Zhang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xu Wang
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Yinghui Xu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xingyu Lin
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Xiaobo Ma
affiliation:
name:The First Hospital of Jilin University
address:
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Ye Guo
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Shi Qiu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Guoguang Shao
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
type:Person
name:Zhiguang Yang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Kewei Ma
url:http://orcid.org/0000-0003-2987-576X
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Journal of Cancer Research and Clinical Oncology
issn:
1432-1335
0171-5216
volumeNumber:149
Organization:
name:Springer Berlin Heidelberg
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Chao Sun
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Yunpeng Liu
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Peng Zhang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Xu Wang
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Yinghui Xu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Xingyu Lin
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Xiaobo Ma
affiliation:
name:The First Hospital of Jilin University
address:
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Ye Guo
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Shi Qiu
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Guoguang Shao
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
name:Zhiguang Yang
affiliation:
name:The First Hospital of Jilin University
address:
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
name:Kewei Ma
url:http://orcid.org/0000-0003-2987-576X
affiliation:
name:The First Hospital of Jilin University
address:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
type:PostalAddress
type:Organization
email:[email protected]
PostalAddress:
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Pathological Department, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China
name:Cancer Center, The First Hospital of Jilin University, Changchun, China
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {🔗}(152)
- What's the financial outcome of https://www.springernature.com/gp/authors?
- How much does https://link.springernature.com/home/ make?
- https://order.springer.com/public/cart's revenue stream
- See how much https://submission.nature.com/new-submission/432/3 makes per month
- How profitable is https://orcid.org/0000-0003-2987-576X?
- How much does https://www.springernature.com/gp/librarians/licensing/agc/journals make?
- How much money does https://doi.org/10.3390%2Fjcm7060153 generate?
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=An%20update%20on%20predictive%20biomarkers%20for%20treatment%20selection%20in%20non-small%20cell%20lung%20cancer&journal=J%20Clin%20Med&doi=10.3390%2Fjcm7060153&volume=20167&issue=6&publication_year=2018&author=Ahmadzada%2CT&author=Kao%2CS&author=Reid%2CG
- https://doi.org/10.1093%2Fannonc%2Fmdy540 income
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30566590 gross monthly?
- How much cash flow does http://scholar.google.com/scholar_lookup?&title=Safety%20and%20efficacy%20of%20nivolumab%20in%20combination%20with%20S-1%2Fcapecitabine%20plus%20oxaliplatin%20in%20patients%20with%20previously%20untreated%2C%20unresectable%2C%20advanced%2C%20or%20recurrent%20gastric%2Fgastroesophageal%20junction%20cancer%3A%20interim%20results%20of%20a%20randomized%2C%20phase%20II%20trial%20%28ATTRACTION-4%29&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdy540&volume=30&issue=2&pages=250-258&publication_year=2019&author=Boku%2CN&author=Ryu%2CMH&author=Kato%2CK have monthly?
- Learn how profitable https://doi.org/10.3322%2Fcaac.21609 is on a monthly basis
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Global%20cancer%20statistics%202018%3A%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries%20%28vol%2068%2C%20pg%20394%2C%202018%29&journal=Ca-a%20Cancer%20J%20Clin&doi=10.3322%2Fcaac.21609&volume=70&issue=4&pages=313-313&publication_year=2020&author=Bray%2CF&author=Ferlay%2CJ&author=Soerjomataram%2CI?
- Discover the revenue of https://doi.org/10.1200%2FJCO.2019.37.15_suppl.8504
- What's the income of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20nivolumab%20%28N%29%20or%20nivolumab%20plus%20ipilimumab%20%28NI%29%20for%20resectable%20non-small%20cell%20lung%20cancer%20%28NSCLC%29%3A%20clinical%20and%20correlative%20results%20from%20the%20NEOSTAR%20study&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2019.37.15_suppl.8504&volume=37&issue=15_suppl&pages=8504-8504&publication_year=2019&author=Cascone%2CT&author=William%2CWN&author=Weissferdt%2CA?
- Check the income stats for https://doi.org/10.1016%2Fj.athoracsur.2017.03.038
- What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28838509?
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572805 earn?
- Find out how much http://scholar.google.com/scholar_lookup?&title=Initial%20experience%20with%20lung%20cancer%20resection%20after%20treatment%20with%20T-cell%20checkpoint%20inhibitors&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2017.03.038&volume=104&issue=3&pages=e217-e218&publication_year=2017&author=Chaft%2CJE&author=Hellmann%2CMD&author=Velez%2CMJ earns monthly
- What's the income generated by https://doi.org/10.21037%2Ftlcr.2018.07.15 each month?
- What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=30393603?
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193911's financial summary
- http://scholar.google.com/scholar_lookup?&title=Combination%20chemotherapy%20and%20immunotherapy%20in%20metastatic%20non-small%20cell%20lung%20cancer%3A%20a%20setback%20for%20personalized%20medicine%3F&journal=Transl%20Lung%20Cancer%20Res&doi=10.21037%2Ftlcr.2018.07.15&volume=7&pages=S208-S210&publication_year=2018&author=Chatwal%2CMS&author=Tanvetyanon%2CT income
- What's the monthly money flow for https://doi.org/10.1056%2FNEJMoa1716078?
- What's the revenue for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29658848?
- Check the income stats for http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223617
- What's the profit of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20PD-1%20blockade%20in%20resectable%20lung%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1716078&volume=378&issue=21&pages=1976-1986&publication_year=2018&author=Forde%2CPM&author=Chaft%2CJE&author=Smith%2CKN?
- What are the total earnings of https://doi.org/10.1056%2FNEJMoa1801005?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29658856 make?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20plus%20chemotherapy%20in%20metastatic%20non-small-cell%20lung%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1801005&volume=378&issue=22&pages=2078-2092&publication_year=2018&author=Gandhi%2CL&author=Rodr%C3%ADguez-Abreu%2CD&author=Gadgeel%2CS?
- Earnings of https://doi.org/10.1016%2Fj.jtho.2020.01.017
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32036071's financial summary
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20PD-1%20inhibitor%20%28Sintilimab%29%20in%20NSCLC&journal=J%20Thorac%20Oncol&doi=10.1016%2Fj.jtho.2020.01.017&volume=15&issue=5&pages=816-826&publication_year=2020&author=Gao%2CS&author=Li%2CN&author=Gao%2CS produce monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32803520 generate monthly?
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Striving%20toward%20improved%20outcomes%20for%20surgically%20resectable%20non-small%20cell%20lung%20cancer%3A%20the%20promise%20and%20challenges%20of%20neoadjuvant%20immunotherapy&journal=Curr%20Oncol%20Rep&doi=10.1007%2Fs11912-020-00969-w&volume=22&issue=11&pages=109-109&publication_year=2020&author=Gentzler%2CRD&author=Riley%2CDO&author=Martin%2CLW?
- Check the income stats for https://doi.org/10.1016%2FS1470-2045%2813%2970334-6
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24384493
- How much revenue does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734624 bring in?
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Pathological%20response%20after%20neoadjuvant%20chemotherapy%20in%20resectable%20non-small-cell%20lung%20cancers%3A%20proposal%20for%20the%20use%20of%20major%20pathological%20response%20as%20a%20surrogate%20endpoint&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2813%2970334-6&volume=15&issue=1&pages=e42-50&publication_year=2014&author=Hellmann%2CMD&author=Chaft%2CJE&author=William%2CWN
- How much money does https://doi.org/10.1038%2Fs41586-019-1922-8 make?
- Find out how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31942075 earns monthly
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762581 earn?
- How much cash flow does http://scholar.google.com/scholar_lookup?&title=B%20cells%20and%20tertiary%20lymphoid%20structures%20promote%20immunotherapy%20response&journal=Nature&doi=10.1038%2Fs41586-019-1922-8&volume=577&pages=549-555&publication_year=2020&author=Helmink%2CBA&author=Reddy%2CSM&author=Gao%2CJ have monthly?
- https://doi.org/10.1016%2Fj.athoracsur.2013.04.050 income
- See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23782644 makes per month
- How much does http://scholar.google.com/scholar_lookup?&title=A%20clinical%20risk%20model%20for%20the%20evaluation%20of%20bronchopleural%20fistula%20in%20non-small%20cell%20lung%20cancer%20after%20pneumonectomy&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2013.04.050&volume=96&issue=2&pages=419-424&publication_year=2013&author=Hu%2CXF&author=Duan%2CL&author=Jiang%2CGN earn?
- What is the monthly revenue of https://doi.org/10.1016%2Fj.athoracsur.2009.06.024?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19853117 pull in monthly?
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Risk%20factor%20comparison%20and%20clinical%20analysis%20of%20early%20and%20late%20bronchopleural%20fistula%20after%20non-small%20cell%20lung%20cancer%20surgery&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2009.06.024&volume=88&issue=5&pages=1589-1593&publication_year=2009&author=Jichen%2CQV&author=Chen%2CG&author=Jiang%2CG?
- Get to know what's the income of https://doi.org/10.1093%2Fjjco%2Fhyw037
- How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27052116?
- How much money does http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20therapy%20and%20risk%20of%20bronchopleural%20fistula%20after%20lung%20cancer%20surgery%3A%20a%20systematic%20meta-analysis%20of%2014%20912%20patients&journal=Jpn%20J%20Clin%20Oncol&doi=10.1093%2Fjjco%2Fhyw037&volume=46&issue=6&pages=534-546&publication_year=2016&author=Li%2CS&author=Fan%2CJ&author=Liu%2CJ make?
- How much does https://doi.org/10.1002%2Fijc.32366 make?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31018251 rake in every month?
- How much does http://scholar.google.com/scholar_lookup?&title=PD-%20%28L%291%20inhibitors%20vs.%20chemotherapy%20vs.%20their%20combination%20in%20front-line%20treatment%20for%20NSCLC%3A%20an%20indirect%20comparison&journal=Int%20J%20Cancer&doi=10.1002%2Fijc.32366&volume=145&pages=3011-3021&publication_year=2019&author=Liang%2CH&author=Liu%2CZ&author=Cai%2CX gross monthly?
- What are the earnings of https://doi.org/10.1002%2Fcpt.810?
- How much profit is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28786099 making per month?
- How much does http://scholar.google.com/scholar_lookup?&title=Current%20landscape%20of%20targeted%20therapy%20in%20lung%20cancer&journal=Clin%20Pharmacol%20Ther&doi=10.1002%2Fcpt.810&volume=102&issue=5&pages=757-764&publication_year=2017&author=Mayekar%2CMK&author=Bivona%2CTG make?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Bronchopleural%20fistula%20after%20pneumonectomy%3A%20risk%20factors%20and%20management%2C%20focusing%20on%20open%20window%20thoracostomy&journal=J%20Thorac%20Cardiovasc%20Surg&volume=S0022%E2%80%935223&issue=17&pages=31189-31193&publication_year=2017&author=Mazzella%2CA&author=Pardolesi%2CA&author=Maisonneuve%2CP produce monthly?
- What's https://doi.org/10.1016%2Fj.athoracsur.2005.07.078's gross income?
- Financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16427825
- Find out how much http://scholar.google.com/scholar_lookup?&title=Video-assisted%20thoracic%20surgery%20lobectomy%3A%20experience%20with%201100%20cases&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2005.07.078&volume=81&pages=421-425&publication_year=2006&author=McKenna%2CRJ&author=Houck%2CW&author=Fuller%2CCB earns monthly
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28814907 generate monthly?
- How much profit does http://scholar.google.com/scholar_lookup?&title=New%20prognostic%20biomarkers%20and%20therapeutic%20effect%20of%20bevacizumab%20for%20patients%20with%20non-small-cell%20lung%20cancer&journal=Lung%20Cancer%28Auckl%29&volume=8&pages=91-99&publication_year=2017&author=Niki%2CM&author=Yokoi%2CT&author=Kurata%2CT make?
- What's the monthly income of https://doi.org/10.1016%2FS0140-6736%2813%2962159-5?
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022989 net monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=Preoperative%20chemotherapy%20for%20non-small-cell%20lung%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20individual%20participant%20data&journal=Lancet&doi=10.1016%2FS0140-6736%2813%2962159-5&volume=383&issue=9928&pages=1561-1571&publication_year=2014 pull in?
- Explore the financials of https://doi.org/10.1097%2F01.sla.0000234892.79056.63
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16926568 make?
- See how much http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856541 makes per month
- How much does http://scholar.google.com/scholar_lookup?&title=Thoracoscopic%20lobectomy%20is%20a%20safe%20and%20versatile%20procedure%3A%20experience%20with%20500%20consecutive%20patients&journal=Ann%20Surg&doi=10.1097%2F01.sla.0000234892.79056.63&volume=244&pages=420-425&publication_year=2006&author=Onaitis%2CMW&author=Petersen%2CRP&author=Balderson%2CSS pull in?
- How much profit does https://doi.org/10.1097%2FJTO.0b013e318247504a generate?
- What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22481232?
- How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465940 have monthly?
- Earnings of http://scholar.google.com/scholar_lookup?&title=Histopathologic%20response%20criteria%20predict%20survival%20of%20patients%20with%20resected%20lung%20cancer%20after%20neoadjuvant%20chemotherapy&journal=J%20Thorac%20Oncol&doi=10.1097%2FJTO.0b013e318247504a&volume=7&issue=5&pages=825-832&publication_year=2012&author=Pataer%2CA&author=Kalhor%2CN&author=Correa%2CAM
- https://doi.org/10.1016%2Fj.athoracsur.2015.06.026 income
- Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26303974 is on a monthly basis
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=A%20predictive%20score%20for%20bronchopleural%20fistula%20established%20using%20the%20French%20database%20epithor&journal=Ann%20Thorac%20Surg&doi=10.1016%2Fj.athoracsur.2015.06.026&volume=101&issue=1&pages=287-293&publication_year=2016&author=Pforr%2CA&author=Pages%2CPB&author=Baste%2CJM each month?
- What's the monthly money flow for https://doi.org/10.1016%2FS1470-2045%2820%2930453-8?
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32979984's total income per month
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20chemotherapy%20and%20nivolumab%20in%20resectable%20non-small-cell%20lung%20cancer%20%28NADIM%29%3A%20an%20open-label%2C%20multicentre%2C%20single-arm%2C%20phase%202%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2820%2930453-8&volume=21&issue=11&pages=1413-1422&publication_year=2020&author=Provencio%2CM&author=Nadal%2CE&author=Insa%2CA generate?
- Discover the revenue of https://doi.org/10.1378%2Fchest.12-2360
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Treatment%20of%20stage%20III%20non-small%20cell%20lung%20cancer%20diagnosis%20and%20management%20of%20lung%20cancer%2C%203rd%20ed%3A%20American%20college%20of%20chest%20physicians%20evidence-based%20clinical%20practice%20guidelines&journal=Chest&doi=10.1378%2Fchest.12-2360&volume=143&issue=5&pages=E314-E340&publication_year=2013&author=Ramnath%2CN&author=Dilling%2CTJ&author=Harris%2CLJ?
- How much does https://doi.org/10.1016%2FS1470-2045%2820%2930140-6 earn?
- Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32386568
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20atezolizumab%20and%20chemotherapy%20in%20patients%20with%20resectable%20non-small%20cell%20lung%20cancer%3A%20an%20open-label%2C%20multicentre%20single-arm%2C%20phase%202%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2820%2930140-6&volume=21&issue=6&pages=786-795&publication_year=2020&author=Shu%2CCA&author=Gainor%2CJF&author=Awad%2CMM
- How much does https://doi.org/10.1016%2Fj.jtho.2016.05.024 gross monthly?
- What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27296106?
- How much does http://scholar.google.com/scholar_lookup?&title=Clinicopathologic%20features%20of%20advanced%20squamous%20NSCLC&journal=J%20Thorac%20Oncol&doi=10.1016%2Fj.jtho.2016.05.024&volume=11&issue=9&pages=1411-1422&publication_year=2016&author=Socinski%2CMA&author=Obasaju%2CC&author=Gandara%2CD pull in monthly?
- What's the monthly money flow for https://doi.org/10.1056%2FNEJMoa1716948?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29863955 make?
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20for%20first-line%20treatment%20of%20metastatic%20nonsquamous%20NSCLC&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1716948&volume=378&pages=2288-2301&publication_year=2018&author=Socinski%2CMA&author=Jotte%2CRM&author=Cappuzzo%2CF
- How much does https://doi.org/10.1126%2Fscience.aax0182 bring in each month?
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32001626 make?
- How much income is http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789854 earning monthly?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Neoadjuvant%20checkpoint%20blockade%20for%20cancer%20immunotherapy&journal=Science&doi=10.1126%2Fscience.aax0182&volume=367&publication_year=2020&author=Topalian%2CSL&author=Taube%2CJM&author=Pardoll%2CDM bring in?
- How much money does https://doi.org/10.1097%2FJTO.0b013e3182774108 make?
- Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23287849 is on a monthly basis
- How much money does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549050 make?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Computed%20tomography%20RECIST%20assessment%20of%20histopathologic%20response%20and%20prediction%20of%20survival%20in%20patients%20with%20resectable%20non-small-cell%20lung%20cancer%20after%20neoadjuvant%20chemotherapy&journal=J%20Thorac%20Oncol&doi=10.1097%2FJTO.0b013e3182774108&volume=8&issue=2&pages=222-228&publication_year=2013&author=William%2CWN&author=Pataer%2CA&author=Kalhor%2CN?
- Discover the revenue of https://doi.org/10.1200%2FJCO.2018.36.15_suppl.e15125
- How much revenue does http://scholar.google.com/scholar_lookup?&title=A%20first-in-human%20phase%201a%20trial%20of%20sintilimab%20%28IBI308%29%2C%20a%20monoclonal%20antibody%20targeting%20programmed%20death-1%20%28PD-1%29%2C%20in%20Chinese%20patients%20with%20advanced%20solid%20tumors&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2018.36.15_suppl.e15125&volume=36&issue=15&publication_year=2018&author=Xu%2CJ-M&author=Jia%2CR&author=Wang%2CY produce monthly?
- How much cash flow does https://doi.org/10.1200%2FJCO.19.00075 have monthly?
- What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31194613's gross income?
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Erlotinib%20versus%20gemcitabine%20plus%20cisplatin%20as%20neoadjuvant%20treatment%20of%20stage%20IIIA-N2%20EGFR-mutant%20non-small-cell%20lung%20cancer%20%28EMERGING-CTONG%201103%29%3A%20a%20randomized%20phase%20II%20study&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.19.00075&volume=37&issue=25&pages=2235-2245&publication_year=2019&author=Zhong%2CWZ&author=Chen%2CKN&author=Chen%2CC
- How much profit does https://citation-needed.springer.com/v2/references/10.1007/s00432-021-03896-w?format=refman&flavour=references make?
- How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chao%20Sun generate?
- Learn how profitable https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chao%20Sun%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en is on a monthly basis
- What's the monthly money flow for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yunpeng%20Liu?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yunpeng%20Liu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in each month?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Peng%20Zhang earn?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Peng%20Zhang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in?
- How much cash flow does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xu%20Wang have monthly?
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xu%20Wang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yinghui%20Xu make?
- Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yinghui%20Xu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xingyu%20Lin generate?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xingyu%20Lin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in?
- Get to know what's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Xiaobo%20Ma
- What's the revenue for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Xiaobo%20Ma%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ye%20Guo's total income per month
- What's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ye%20Guo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Shi%20Qiu's revenue stream
- Get to know https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Shi%20Qiu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's earnings
- How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Guoguang%20Shao generate?
- How much cash flow does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Guoguang%20Shao%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have monthly?
- What's the profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Zhiguang%20Yang?
- What are the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Zhiguang%20Yang%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What is the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kewei%20Ma?
- What's the profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kewei%20Ma%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Income figures for https://static-content.springer.com/esm/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_MOESM1_ESM.gif
- How much revenue does https://static-content.springer.com/esm/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_MOESM2_ESM.gif generate?
- What is the monthly revenue of https://static-content.springer.com/esm/art%3A10.1007%2Fs00432-021-03896-w/MediaObjects/432_2021_3896_MOESM3_ESM.docx?
- What's the financial gain of https://s100.copyright.com/AppDispatchServlet?title=Interim%20analysis%20of%20the%20efficiency%20and%20safety%20of%20neoadjuvant%20PD-1%20inhibitor%20%28sintilimab%29%20combined%20with%20chemotherapy%20%28nab-paclitaxel%20and%20carboplatin%29%20in%20potentially%20resectable%20stage%20IIIA%2FIIIB%20non-small%20cell%20lung%20cancer%3A%20a%20single-arm%2C%20phase%202%20trial&author=Chao%20Sun%20et%20al&contentID=10.1007%2Fs00432-021-03896-w©right=The%20Author%28s%29%2C%20under%20exclusive%20licence%20to%20Springer-Verlag%20GmbH%20Germany%2C%20part%20of%20Springer%20Nature&publication=0171-5216&publicationDate=2022-02-22&publisherName=SpringerNature&orderBeanReset=true?
- How much revenue does https://crossmark.crossref.org/dialog/?doi=10.1007/s00432-021-03896-w produce monthly?
- What's the monthly money flow for https://citation-needed.springer.com/v2/references/10.1007/s00432-021-03896-w?format=refman&flavour=citation?
- How much does https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral gross monthly?
- What are the earnings of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research?
- What's the total monthly financial gain of https://www.springernature.com/gp/products?
- How much revenue does https://www.springernature.com/gp/librarians generate?
- What are the total earnings of https://www.springernature.com/gp/societies?
- What's the monthly income of https://www.springernature.com/gp/partners?
- Financial intake of https://www.springer.com/
- Earnings of https://www.nature.com/
- How much profit does https://www.biomedcentral.com/ make?
- Learn how profitable https://www.palgrave.com/ is on a monthly basis
- How much money does https://www.apress.com/ generate?
- What is the monthly revenue of https://www.springernature.com/gp/legal/ccpa?
- https://www.springernature.com/gp/info/accessibility income
- How much does https://support.springernature.com/en/support/home make?
- How much does https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations rake in every month?
- Discover the revenue of https://www.springernature.com/
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
- Video.js
CDN Services {📦}
- Crossref